Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 265

1.

The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations.

Huang G, Zhao X, Wang L, Elf S, Xu H, Zhao X, Sashida G, Zhang Y, Liu Y, Lee J, Menendez S, Yang Y, Yan X, Zhang P, Tenen DG, Osato M, Hsieh JJ, Nimer SD.

Blood. 2011 Dec 15;118(25):6544-52. doi: 10.1182/blood-2010-11-317909. Epub 2011 Oct 19.

2.

Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.

Zhao X, Chen A, Yan X, Zhang Y, He F, Hayashi Y, Dong Y, Rao Y, Li B, Conway RM, Maiques-Diaz A, Elf SE, Huang N, Zuber J, Xiao Z, Tse W, Tenen DG, Wang Q, Chen W, Mulloy JC, Nimer SD, Huang G.

Blood. 2014 Mar 13;123(11):1729-38. doi: 10.1182/blood-2013-03-489575. Epub 2014 Jan 21.

3.

Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARα promoter region.

Sakamoto K, Imamura T, Yano M, Yoshida H, Fujiki A, Hirashima Y, Hosoi H.

Blood Cancer J. 2014 Apr 25;4:e205. doi: 10.1038/bcj.2014.25.

4.

Subnuclear targeting of Runx1 is required for synergistic activation of the myeloid specific M-CSF receptor promoter by PU.1.

Li X, Vradii D, Gutierrez S, Lian JB, van Wijnen AJ, Stein JL, Stein GS, Javed A.

J Cell Biochem. 2005 Nov 1;96(4):795-809.

PMID:
16149049
5.

Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy.

Gu X, Hu Z, Ebrahem Q, Crabb JS, Mahfouz RZ, Radivoyevitch T, Crabb JW, Saunthararajah Y.

J Biol Chem. 2014 May 23;289(21):14881-95. doi: 10.1074/jbc.M114.562447. Epub 2014 Apr 2.

6.

Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.

Harada Y, Harada H.

J Cell Physiol. 2009 Jul;220(1):16-20. doi: 10.1002/jcp.21769. Review.

PMID:
19334039
7.

High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.

Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T.

Blood. 2004 Mar 15;103(6):2316-24. Epub 2003 Nov 13.

8.

Mixed lineage leukaemia histone methylases 1 collaborate with ERα to regulate HOXA10 expression in AML.

Yao J, Fang LC, Yang ZL, Huang H, Li Y, Deng J, Zheng J.

Biosci Rep. 2014 Dec 8;34(6):e00156. doi: 10.1042/BSR20140116.

9.

Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription.

Chang PY, Hom RA, Musselman CA, Zhu L, Kuo A, Gozani O, Kutateladze TG, Cleary ML.

J Mol Biol. 2010 Jul 9;400(2):137-44. doi: 10.1016/j.jmb.2010.05.005. Epub 2010 May 7.

10.

Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells.

Goyama S, Schibler J, Cunningham L, Zhang Y, Rao Y, Nishimoto N, Nakagawa M, Olsson A, Wunderlich M, Link KA, Mizukawa B, Grimes HL, Kurokawa M, Liu PP, Huang G, Mulloy JC.

J Clin Invest. 2013 Sep;123(9):3876-88. doi: 10.1172/JCI68557. Epub 2013 Aug 27. Erratum in: J Clin Invest. 2013 Nov 1;123(11):4979.

11.

The +37 kb Cebpa Enhancer Is Critical for Cebpa Myeloid Gene Expression and Contains Functional Sites that Bind SCL, GATA2, C/EBPα, PU.1, and Additional Ets Factors.

Cooper S, Guo H, Friedman AD.

PLoS One. 2015 May 4;10(5):e0126385. doi: 10.1371/journal.pone.0126385. eCollection 2015.

12.

Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.

Gessner A, Thomas M, Castro PG, Büchler L, Scholz A, Brümmendorf TH, Soria NM, Vormoor J, Greil J, Heidenreich O.

Leukemia. 2010 Oct;24(10):1751-9. doi: 10.1038/leu.2010.155. Epub 2010 Aug 5.

PMID:
20686504
13.

Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.

Harada H, Harada Y.

Crit Rev Eukaryot Gene Expr. 2005;15(3):183-96. Review.

PMID:
16390315
14.

Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia.

Harada H, Harada Y, Tanaka H, Kimura A, Inaba T.

Blood. 2003 Jan 15;101(2):673-80. Epub 2002 Sep 5.

15.

PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis.

Huang G, Zhang P, Hirai H, Elf S, Yan X, Chen Z, Koschmieder S, Okuno Y, Dayaram T, Growney JD, Shivdasani RA, Gilliland DG, Speck NA, Nimer SD, Tenen DG.

Nat Genet. 2008 Jan;40(1):51-60. Epub 2007 Nov 11. Erratum in: Nat Genet. 2008 Feb;40(2):255.

PMID:
17994017
16.

Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.

Tsai SC, Shih LY, Liang ST, Huang YJ, Kuo MC, Huang CF, Shih YS, Lin TH, Chiu MC, Liang DC.

Clin Cancer Res. 2015 Aug 1;21(15):3541-51. doi: 10.1158/1078-0432.CCR-14-2203. Epub 2015 Apr 3.

17.

Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.

Niimi H, Harada H, Harada Y, Ding Y, Imagawa J, Inaba T, Kyo T, Kimura A.

Leukemia. 2006 Apr;20(4):635-44.

PMID:
16467864
18.
19.

The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.

Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, Hiddemann W, Behre G.

Blood. 2003 Jan 1;101(1):270-7. Epub 2002 Aug 29.

20.

RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.

Koh CP, Wang CQ, Ng CE, Ito Y, Araki M, Tergaonkar V, Huang G, Osato M.

Leukemia. 2013 Sep;27(9):1793-802. doi: 10.1038/leu.2013.200. Epub 2013 Jul 2. Review.

PMID:
23817177

Supplemental Content

Support Center